Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Seynaeve

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 10, 2018
Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trialM G M Derks, E Bastiaannet, W van de Water, et al.
Breast (Edinburgh, Scotland)|December 10, 2013
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' groupM E Hamaker, C Seynaeve, A N M Wymenga, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 3, 2006
Association between the CHEK2*1100delC germ line mutation and estrogen receptor statusG H de Bock, M J E Mourits, M Schutte, et al.
Breast Cancer Research and Treatment|July 12, 2013
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trialV O Dezentjé, R H N van Schaik, J M Vletter-Bogaartz, et al.
British Journal of Cancer|October 5, 2013
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trialJ M S Bartlett, C L Brookes, T Piper, et al.
The British Journal of Surgery|April 16, 2010
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countriesJ G H van Nes, C Seynaeve, S Jones, et al.
Familial Cancer|February 22, 2015
Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyM R Wevers, M K Schmidt, E G Engelhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2012
Relevant impact of central pathology review on nodal classification in individual breast cancer patientsJ H M J Vestjens, M J Pepels, M de Boer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2013
Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the NetherlandsP M L H Vencken, W Reitsma, M Kriege, et al.
Breast Cancer Research and Treatment|October 20, 2006
Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancerM Kriege, C T M Brekelmans, H Peterse, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|June 10, 2018
Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trialM G M Derks, E Bastiaannet, W van de Water, et al.
Breast (Edinburgh, Scotland)|December 10, 2013
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' groupM E Hamaker, C Seynaeve, A N M Wymenga, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 3, 2006
Association between the CHEK2*1100delC germ line mutation and estrogen receptor statusG H de Bock, M J E Mourits, M Schutte, et al.
Breast Cancer Research and Treatment|July 12, 2013
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trialV O Dezentjé, R H N van Schaik, J M Vletter-Bogaartz, et al.
British Journal of Cancer|October 5, 2013
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trialJ M S Bartlett, C L Brookes, T Piper, et al.
The British Journal of Surgery|April 16, 2010
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countriesJ G H van Nes, C Seynaeve, S Jones, et al.
Familial Cancer|February 22, 2015
Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyM R Wevers, M K Schmidt, E G Engelhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2012
Relevant impact of central pathology review on nodal classification in individual breast cancer patientsJ H M J Vestjens, M J Pepels, M de Boer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2013
Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the NetherlandsP M L H Vencken, W Reitsma, M Kriege, et al.
Breast Cancer Research and Treatment|October 20, 2006
Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancerM Kriege, C T M Brekelmans, H Peterse, et al.
Pageof 11